{"success":true,"data":{"pressRelease":{"id":"52841","rtpr_id":"nBw7cfwKza","ticker":"RLYB","exchange":"NASDAQ","all_tickers":["RLYB"],"title":"Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYB","author":"Business Wire","published_at":"2026-06-02T19:48:00.100Z","article_body":"Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of\nRallybio Corporation - RLYB\n\nFormer Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law\nfirm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed\nmerger of Rallybio Corporation\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.ksfcounsel.com%2Fcases%2Fnasdaqcm-rlyb%2F&esheet=54546595&newsitemid=20260602266487&lan=en-US&anchor=Rallybio+Corporation&index=1&md5=4c5dacd0fa3de3a5de68a10fceba4ef9)\n(NasdaqCM: RLYB) and Avenzo Therapeutics, Inc. Upon completion of the proposed\ntransaction, pre-Transaction Rallybio equityholders are expected to own\napproximately 2.8% of the combined company. KSF is seeking to determine\nwhether the merger and the process that led to it are adequate, or whether the\nmerger is fair to Rallybio shareholders.\n\nIf you would like to discuss your legal rights regarding the proposed\ntransaction, you may, without obligation or cost to you, e-mail or call KSF\nManaging Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com\n(mailto:lewis.kahn@ksfcounsel.com) ) toll free at any time at 855-768-1857, or\nvisit https://www.ksfcounsel.com/cases/nasdaqcm-rlyb/\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.ksfcounsel.com%2Fcases%2Fnasdaqcm-rlyb%2F&esheet=54546595&newsitemid=20260602266487&lan=en-US&anchor=https%3A%2F%2Fwww.ksfcounsel.com%2Fcases%2Fnasdaqcm-rlyb%2F&index=2&md5=f041710d1cd6756a72d3d49e98f7b32f)\nto learn more.\n\nTo learn more about KSF, whose partners include the Former Louisiana Attorney\nGeneral, visit www.ksfcounsel.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.ksfcounsel.com&esheet=54546595&newsitemid=20260602266487&lan=en-US&anchor=www.ksfcounsel.com&index=3&md5=bc63da2e00928401871a13a46288f710)\n.\n\nCONNECT WITH US: Facebook\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.facebook.com%2Fprofile.php%3Fid%3D61575733915628&esheet=54546595&newsitemid=20260602266487&lan=en-US&anchor=Facebook&index=4&md5=40396df36f95336b1f0ef6c6243168b1)\n|| Instagram\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.instagram.com%2Fkahn_swick_and_foti%2F&esheet=54546595&newsitemid=20260602266487&lan=en-US&anchor=Instagram&index=5&md5=72c083a225aabc537895d9160eda1330)\n|| YouTube\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.youtube.com%2F%40kahnswickandfoti&esheet=54546595&newsitemid=20260602266487&lan=en-US&anchor=YouTube&index=6&md5=a3d6ef17b9d9e9324264257fe0e2821e)\n|| TikTok\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.tiktok.com%2F%40kahn.swick.foti&esheet=54546595&newsitemid=20260602266487&lan=en-US&anchor=TikTok&index=7&md5=bfa85d28db59dd0cd4e5f5c8b362f375)\n|| LinkedIn\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fksfcounsel&esheet=54546595&newsitemid=20260602266487&lan=en-US&anchor=LinkedIn&index=8&md5=78a4e5b343fa17d2588bcbe81db4d4ed)\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260602266487/en/\n(https://www.businesswire.com/news/home/20260602266487/en/)\n\nKahn Swick & Foti, LLC\n\nLewis S. Kahn, Managing Partner\n\nlewis.kahn@ksfcounsel.com \n(mailto:lewis.kahn@ksfcounsel.com) \n855-768-1857\n\n1100 Poydras St., Suite 960\n\nNew Orleans, LA 70163\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw7cfwKza","title":"Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYB","author":"Business Wire","ticker":"RLYB","created":"2026-06-02T19:48:00.100Z","tickers":["RLYB"],"exchange":"NASDAQ","article_body":"Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of\nRallybio Corporation - RLYB\n\nFormer Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law\nfirm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed\nmerger of Rallybio Corporation\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.ksfcounsel.com%2Fcases%2Fnasdaqcm-rlyb%2F&esheet=54546595&newsitemid=20260602266487&lan=en-US&anchor=Rallybio+Corporation&index=1&md5=4c5dacd0fa3de3a5de68a10fceba4ef9)\n(NasdaqCM: RLYB) and Avenzo Therapeutics, Inc. Upon completion of the proposed\ntransaction, pre-Transaction Rallybio equityholders are expected to own\napproximately 2.8% of the combined company. KSF is seeking to determine\nwhether the merger and the process that led to it are adequate, or whether the\nmerger is fair to Rallybio shareholders.\n\nIf you would like to discuss your legal rights regarding the proposed\ntransaction, you may, without obligation or cost to you, e-mail or call KSF\nManaging Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com\n(mailto:lewis.kahn@ksfcounsel.com) ) toll free at any time at 855-768-1857, or\nvisit https://www.ksfcounsel.com/cases/nasdaqcm-rlyb/\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.ksfcounsel.com%2Fcases%2Fnasdaqcm-rlyb%2F&esheet=54546595&newsitemid=20260602266487&lan=en-US&anchor=https%3A%2F%2Fwww.ksfcounsel.com%2Fcases%2Fnasdaqcm-rlyb%2F&index=2&md5=f041710d1cd6756a72d3d49e98f7b32f)\nto learn more.\n\nTo learn more about KSF, whose partners include the Former Louisiana Attorney\nGeneral, visit www.ksfcounsel.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.ksfcounsel.com&esheet=54546595&newsitemid=20260602266487&lan=en-US&anchor=www.ksfcounsel.com&index=3&md5=bc63da2e00928401871a13a46288f710)\n.\n\nCONNECT WITH US: Facebook\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.facebook.com%2Fprofile.php%3Fid%3D61575733915628&esheet=54546595&newsitemid=20260602266487&lan=en-US&anchor=Facebook&index=4&md5=40396df36f95336b1f0ef6c6243168b1)\n|| Instagram\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.instagram.com%2Fkahn_swick_and_foti%2F&esheet=54546595&newsitemid=20260602266487&lan=en-US&anchor=Instagram&index=5&md5=72c083a225aabc537895d9160eda1330)\n|| YouTube\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.youtube.com%2F%40kahnswickandfoti&esheet=54546595&newsitemid=20260602266487&lan=en-US&anchor=YouTube&index=6&md5=a3d6ef17b9d9e9324264257fe0e2821e)\n|| TikTok\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.tiktok.com%2F%40kahn.swick.foti&esheet=54546595&newsitemid=20260602266487&lan=en-US&anchor=TikTok&index=7&md5=bfa85d28db59dd0cd4e5f5c8b362f375)\n|| LinkedIn\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fksfcounsel&esheet=54546595&newsitemid=20260602266487&lan=en-US&anchor=LinkedIn&index=8&md5=78a4e5b343fa17d2588bcbe81db4d4ed)\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260602266487/en/\n(https://www.businesswire.com/news/home/20260602266487/en/)\n\nKahn Swick & Foti, LLC\n\nLewis S. Kahn, Managing Partner\n\nlewis.kahn@ksfcounsel.com \n(mailto:lewis.kahn@ksfcounsel.com) \n855-768-1857\n\n1100 Poydras St., Suite 960\n\nNew Orleans, LA 70163\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-06-02T19:48:00.150545599Z","server_sent_at_ms":1780429680150},"received_at":"2026-06-02T19:48:00.223Z","source_url":"https://www.businesswire.com/news/home/20260602266487/en/"},"analysis":{"id":"42273","press_release_id":"52841","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"legal_litigation","narrative":"Kahn Swick & Foti, LLC announced it is investigating the proposed merger between Rallybio Corporation and Avenzo Therapeutics, Inc.\n\nThe law firm is seeking to determine whether the merger process and terms are fair to Rallybio shareholders, noting that pre-transaction Rallybio equityholders are expected to own approximately 2.8% of the combined company.\n\nThis is a routine plaintiff-firm solicitation inviting investors to contact the firm without cost or obligation; it does not represent a new disclosure from Rallybio or a court action.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress."},"keyFigures":{"customDimensions":{"post_merger_ownership_pct":"2.8%"}},"quotedText":"KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger is fair to Rallybio shareholders.","namedEntities":{"people":[{"name":"Charles C. Foti, Jr.","role":"Former Attorney General of Louisiana"},{"name":"Lewis S. Kahn","role":"Managing Partner"}],"products":[],"companies":[{"name":"Kahn Swick & Foti, LLC","relationship":"plaintiff law firm"},{"name":"Rallybio Corporation","ticker":"RLYB"},{"name":"Avenzo Therapeutics, Inc.","relationship":"acquirer"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm shareholder solicitation issued by Kahn Swick & Foti, LLC. No new disclosure from the issuer; no certified class, no settlement. Boilerplate investigation notice regarding a proposed merger."},"tickerRelevance":{"others":[],"primary":"RLYB"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Kahn Swick & Foti, LLC announced it is investigating the proposed merger between Rallybio Corporation and Avenzo Therapeutics, Inc.\n\nThe law firm is seeking to determine whether the merger process and terms are fair to Rallybio shareholders, noting that pre-transaction Rallybio equityholders are expected to own approximately 2.8% of the combined company.\n\nThis is a routine plaintiff-firm solicitation inviting investors to contact the firm without cost or obligation; it does not represent a new disclosure from Rallybio or a court action.","key_figures":{"customDimensions":{"post_merger_ownership_pct":"2.8%"}},"named_entities":{"people":[{"name":"Charles C. Foti, Jr.","role":"Former Attorney General of Louisiana"},{"name":"Lewis S. Kahn","role":"Managing Partner"}],"products":[],"companies":[{"name":"Kahn Swick & Foti, LLC","relationship":"plaintiff law firm"},{"name":"Rallybio Corporation","ticker":"RLYB"},{"name":"Avenzo Therapeutics, Inc.","relationship":"acquirer"}],"dollarAmounts":[]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-02T19:48:48.914Z","global_importance":15,"audience_relevance":10,"importance_components":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":48684,"modelName":"george-droid-qwen-72b"}}